Literature DB >> 27267764

Autoinflammatory Skin Disorders: The Inflammasomme in Focus.

Prajwal Gurung1, Thirumala-Devi Kanneganti2.   

Abstract

Autoinflammatory skin disorders are a group of heterogeneous diseases that include diseases such as cryopyrin-associated periodic syndrome (CAPS) and familial Mediterranean fever (FMF). Therapeutic strategies targeting IL-1 cytokines have proved helpful in ameliorating some of these diseases. While inflammasomes are the major regulators of IL-1 cytokines, inflammasome-independent complexes can also process IL-1 cytokines. Herein, we focus on recent advances in our understanding of how IL-1 cytokines, stemming from inflammasome-dependent and -independent pathways are involved in the regulation of skin conditions. Importantly, we discuss several mouse models of skin inflammation generated to help elucidate the basic cellular and molecular effects and modulation of IL-1 in the skin. Such models offer perspectives on how these signaling pathways could be targeted to improve therapeutic approaches in the treatment of these rare and debilitating inflammatory skin disorders.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CAPS; FMF; IL-1; NLRP3; Ptpn6; Sharpin; autoimmune; inflammasome; inflammatory

Mesh:

Substances:

Year:  2016        PMID: 27267764      PMCID: PMC4925313          DOI: 10.1016/j.molmed.2016.05.003

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  141 in total

1.  Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression.

Authors:  Antonia Fettelschoss; Magdalena Kistowska; Salomé LeibundGut-Landmann; Hans-Dietmar Beer; Pål Johansen; Gabriela Senti; Emmanuel Contassot; Martin F Bachmann; Lars E French; Annette Oxenius; Thomas M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

2.  Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment.

Authors:  Sule Apras Bilgen; Levent Kilic; Ali Akdogan; Sedat Kiraz; Umut Kalyoncu; Omer Karadag; Ihsan Ertenli; Ismail Dogan; Meral Calguneri
Journal:  J Clin Rheumatol       Date:  2011-10       Impact factor: 3.517

Review 3.  Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature.

Authors:  Salih Ozgocmen; Ozgur Akgul
Journal:  Mod Rheumatol       Date:  2011-05-13       Impact factor: 3.023

4.  Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium.

Authors: 
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

5.  Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells.

Authors:  Eynav Klechevsky; Rimpei Morita; Maochang Liu; Yanying Cao; Sebastien Coquery; Luann Thompson-Snipes; Francine Briere; Damien Chaussabel; Gerard Zurawski; A Karolina Palucka; Yoram Reiter; Jacques Banchereau; Hideki Ueno
Journal:  Immunity       Date:  2008-09-19       Impact factor: 31.745

6.  Use of canakinumab in the cryopyrin-associated periodic syndrome.

Authors:  Helen J Lachmann; Isabelle Kone-Paut; Jasmin B Kuemmerle-Deschner; Kieron S Leslie; Eric Hachulla; Pierre Quartier; Xavier Gitton; Albert Widmer; Neha Patel; Philip N Hawkins
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

7.  Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever.

Authors:  D Zemer; M Pras; E Sohar; M Modan; S Cabili; J Gafni
Journal:  N Engl J Med       Date:  1986-04-17       Impact factor: 91.245

8.  A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses.

Authors:  Guangxun Meng; Fuping Zhang; Ivan Fuss; Atsushi Kitani; Warren Strober
Journal:  Immunity       Date:  2009-06-04       Impact factor: 31.745

9.  Cutting Edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice.

Authors:  Scott B Berger; Viera Kasparcova; Sandy Hoffman; Barb Swift; Lauren Dare; Michelle Schaeffer; Carol Capriotti; Michael Cook; Joshua Finger; Angela Hughes-Earle; Philip A Harris; William J Kaiser; Edward S Mocarski; John Bertin; Peter J Gough
Journal:  J Immunol       Date:  2014-05-12       Impact factor: 5.422

10.  Sharpin prevents skin inflammation by inhibiting TNFR1-induced keratinocyte apoptosis.

Authors:  Snehlata Kumari; Younes Redouane; Jaime Lopez-Mosqueda; Ryoko Shiraishi; Malgorzata Romanowska; Stefan Lutzmayer; Jan Kuiper; Conception Martinez; Ivan Dikic; Manolis Pasparakis; Fumiyo Ikeda
Journal:  Elife       Date:  2014-12-02       Impact factor: 8.140

View more
  25 in total

1.  ASK1/2 signaling promotes inflammation in a mouse model of neutrophilic dermatosis.

Authors:  Sarang Tartey; Prajwal Gurung; Tejasvi Krishna Dasari; Amanda Burton; Thirumala-Devi Kanneganti
Journal:  J Clin Invest       Date:  2018-04-09       Impact factor: 14.808

2.  Taurine and N-Bromotaurine in Topical Treatment of Psoriasis.

Authors:  Anthony M Kyriakopoulos; Markus Nagl; Ramesh C Gupta; Janusz Marcinkiewicz
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 3.  The Regulation and Modification of GSDMD Signaling in Diseases.

Authors:  Zihao Li; Senlin Ji; Mei-Ling Jiang; Yun Xu; Cun-Jin Zhang
Journal:  Front Immunol       Date:  2022-06-14       Impact factor: 8.786

Review 4.  An update on cell intrinsic negative regulators of the NLRP3 inflammasome.

Authors:  Barun Poudel; Prajwal Gurung
Journal:  J Leukoc Biol       Date:  2018-01-26       Impact factor: 4.962

5.  Cutting Edge: Dysregulated CARD9 Signaling in Neutrophils Drives Inflammation in a Mouse Model of Neutrophilic Dermatoses.

Authors:  Sarang Tartey; Prajwal Gurung; Parimal Samir; Amanda Burton; Thirumala-Devi Kanneganti
Journal:  J Immunol       Date:  2018-08-06       Impact factor: 5.422

Review 6.  Function and regulation of IL-1α in inflammatory diseases and cancer.

Authors:  Ankit Malik; Thirumala-Devi Kanneganti
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

7.  Bruton tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes IL-1β-mediated colitis.

Authors:  Liming Mao; Atsushi Kitani; Eitaro Hiejima; Kim Montgomery-Recht; Wenchang Zhou; Ivan Fuss; Adrian Wiestner; Warren Strober
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 8.  TRIM Proteins in Inflammation: from Expression to Emerging Regulatory Mechanisms.

Authors:  Luting Yang; Haibin Xia
Journal:  Inflammation       Date:  2021-01-07       Impact factor: 4.092

Review 9.  Eavesdropping on the conversation between immune cells and the skin epithelium.

Authors:  Shoiab Bukhari; Aaron F Mertz; Shruti Naik
Journal:  Int Immunol       Date:  2019-07-13       Impact factor: 5.071

10.  NLRP3 Inhibition Ameliorates Severe Cutaneous Autoimmune Manifestations in a Mouse Model of Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy-Like Disease.

Authors:  Feng Zhu; Jami Willette-Brown; Jian Zhang; Elise M N Ferre; Zhonghe Sun; Xiaolin Wu; Michail S Lionakis; Yinling Hu
Journal:  J Invest Dermatol       Date:  2020-11-11       Impact factor: 7.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.